AZUSA, CA--(MARKET WIRE)--Aug 2, 2007 -- Viral Genetics, Inc. (OTC BB:VRAL.OB - News) has retained the services of Michael Agadjanyan, PhD, of the Institute for Molecular Medicine as Acting Director of Preclinical Development. Dr. Agadjanyan has been retained primarily to assist with the implementation of “translational” studies mandated by the development plan for VGV-1, the Company’s HIV/AIDS drug candidate, as outlined by the Scientific Advisory Board.
